JP2019535232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535232A5 JP2019535232A5 JP2019502698A JP2019502698A JP2019535232A5 JP 2019535232 A5 JP2019535232 A5 JP 2019535232A5 JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019535232 A5 JP2019535232 A5 JP 2019535232A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding portion
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022035222A JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1614162.4 | 2016-08-18 | ||
| GBGB1614162.4A GB201614162D0 (en) | 2016-08-18 | 2016-08-18 | Antibodies, uses thereof and conjugates thereof |
| PCT/GB2017/052448 WO2018033749A1 (en) | 2016-08-18 | 2017-08-18 | Anti-psma antibodies, uses thereof and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035222A Division JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535232A JP2019535232A (ja) | 2019-12-12 |
| JP2019535232A5 true JP2019535232A5 (https=) | 2020-09-17 |
| JP7039554B2 JP7039554B2 (ja) | 2022-03-22 |
Family
ID=57045541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502698A Active JP7039554B2 (ja) | 2016-08-18 | 2017-08-18 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
| JP2022035222A Active JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035222A Active JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11059903B2 (https=) |
| EP (2) | EP3500595B1 (https=) |
| JP (2) | JP7039554B2 (https=) |
| CN (1) | CN110049999B (https=) |
| ES (1) | ES2983492T3 (https=) |
| GB (1) | GB201614162D0 (https=) |
| WO (1) | WO2018033749A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| US12059473B2 (en) * | 2018-03-29 | 2024-08-13 | Ambrx, Inc. | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates |
| BR112021026663A2 (pt) * | 2019-07-02 | 2022-04-12 | Telix Int Pty Ltd | Anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatal |
| WO2021050656A1 (en) | 2019-09-11 | 2021-03-18 | The Trustees Of The Univeristy Of Pennsylvania | Compositions and methods comprising prostate stem cell antigen (psca) chimeric antigen receptors (cars) |
| WO2021098834A1 (zh) * | 2019-11-22 | 2021-05-27 | 上海一宸医药科技有限公司 | Psma抗体及其应用 |
| CN110922486B (zh) * | 2020-02-18 | 2020-05-22 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| WO2024182569A2 (en) * | 2023-02-28 | 2024-09-06 | Eisai R&D Management Co., Ltd. | Anti-psma antibodies, conjugates, and methods of use |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
| CN116271081A (zh) * | 2023-04-04 | 2023-06-23 | 上海愿智生物技术有限公司 | 一种抗体偶联药物yc1605及其药物组合物和应用 |
| WO2026044149A2 (en) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Synthesis of drug-linker combinations for antibody-drug conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| CA2232818C (en) | 1996-07-24 | 2006-06-06 | Philips Electronics N.V. | Improvements in and relating to optically readable discs and disc recording apparatus |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| US20040136998A1 (en) | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| BRPI0607796A2 (pt) * | 2005-02-18 | 2009-06-13 | Medarex Inc | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica |
| NZ556661A (en) | 2005-02-18 | 2010-10-29 | Medarex Inc | Human monoclonal antibodies to prostate specific membrance antigen (PSMA) |
| WO2009017823A2 (en) * | 2007-08-01 | 2009-02-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| KR20100090684A (ko) | 2007-10-09 | 2010-08-16 | 폴리테릭스 리미티드 | 신규한 접합 단백질 및 펩티드 |
| CN101891818B (zh) * | 2009-01-16 | 2012-07-25 | 中国人民解放军第四军医大学 | 抗人前列腺特异性膜抗原胞外区单链抗体及其应用 |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| MX2014015682A (es) * | 2012-06-19 | 2015-07-23 | Polytherics Ltd | Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos. |
| MX2015005122A (es) * | 2012-10-24 | 2015-10-29 | Polytherics Ltd | Conjugados de farmaco-proteina novedosos. |
| NO2789793T3 (https=) | 2012-10-24 | 2018-01-27 | ||
| WO2015142314A1 (en) * | 2013-03-15 | 2015-09-24 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| JP6908964B2 (ja) * | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| US20150110814A1 (en) * | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| ES2895623T3 (es) * | 2014-05-22 | 2022-02-22 | Byondis Bv | Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| EP3220956B1 (en) * | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
-
2016
- 2016-08-18 GB GBGB1614162.4A patent/GB201614162D0/en not_active Ceased
-
2017
- 2017-08-18 CN CN201780044227.8A patent/CN110049999B/zh active Active
- 2017-08-18 EP EP17757849.9A patent/EP3500595B1/en active Active
- 2017-08-18 WO PCT/GB2017/052448 patent/WO2018033749A1/en not_active Ceased
- 2017-08-18 JP JP2019502698A patent/JP7039554B2/ja active Active
- 2017-08-18 EP EP24173428.4A patent/EP4403226A3/en active Pending
- 2017-08-18 US US16/303,600 patent/US11059903B2/en active Active
- 2017-08-18 ES ES17757849T patent/ES2983492T3/es active Active
-
2022
- 2022-03-08 JP JP2022035222A patent/JP7486538B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535232A5 (https=) | ||
| JP2019527561A5 (https=) | ||
| Tran et al. | 99mTc-maEEE-ZHER2: 342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors | |
| Wängler et al. | Antibody− dendrimer conjugates: The number, not the size of the dendrimers, determines the immunoreactivity | |
| Hong et al. | Positron emission tomography imaging of prostate cancer | |
| Adumeau et al. | A pretargeted approach for the multimodal PET/NIRF imaging of colorectal cancer | |
| Westerlund et al. | Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic affibody molecules | |
| TWI795415B (zh) | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 | |
| ES2800602T3 (es) | Procedimientos y composiciones relacionados con los fragmentos de anticuerpos monocatenarios que se unen a la glucoproteína 72 asociada a tumor (TAG-72) | |
| JP2017531028A5 (https=) | ||
| JP2019511201A5 (https=) | ||
| CA2646329A1 (en) | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting | |
| TWI780082B (zh) | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 | |
| JP2020504607A5 (https=) | ||
| Maina et al. | From bench to bed: New gastrin-releasing peptide receptor-directed radioligands and their use in prostate cancer | |
| ES2925224T3 (es) | Anticuerpos monoclonales humanos contra EphA4 y su uso | |
| EP4403226A3 (en) | Anti-psma antibodies, uses thereof and conjugates thereof | |
| Luo et al. | Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer | |
| Spiegelberg et al. | CD44v6‐Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody‐Based Approaches | |
| CA3168866A1 (en) | Anti-meflin antibody for use in treatment of cancer in subject having cancer, and pharmaceutical composition comprising the antibody | |
| Luca et al. | Peptide ligands specifically targeting HER2 Receptor and the role played by a synthetic model system of the receptor extracellular domain: Hypothesized future perspectives | |
| Uehara et al. | 67/68Ga-labeling agent that liberates 67/68Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels | |
| Altai et al. | Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine | |
| Niu et al. | Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression | |
| Altıparmak Güleç et al. | Radiopharmaceuticals developed for 89Zr-Immuno-PET |